Gallbladder neuroendocrine carcinoma diagnosis, treatment and prognosis based on the SEER database: A literature review

Table 1 Clinicopathological features of GB-NEC and GB-ADC

Clinical variable	GB-NEC (n = 287)	GB-ADC (n = 19 484)	P value
Age, mean (range), yr	68 (32-98)	70 (11-104)	0.175
Race, n (%)			0.372
Black	35 (12.2%)	2187 (11.2%)
White	227 (79.1%)	15121 (77.6%)
Other	25 (8.7%)	2127 (10.9%)
Sex, n (%)			0.239
Female	192 (66.9%)	13679 (70.2%)
Male	95 (33.1%)	5805 (29.8%)
Grade, n (%)			< 0.001
I	9 (3.1%)	2220 (11.4%)
II	7 (2.4%)	5853 (30.0%)
III	98 (34.1%)	5980 (30.7%)
IV	68 (23.7%)	445 (2.3%)
Unknown	105 (36.6%)	4986 (25.6%)
Survival time, median, 95%CI (mo)	8 (6.6-9.4)	7 (6.8-7.2)	0.079
Histologic type, n (%)
Neuroendocrine carcinoma	149 (51.9%)
Large cell neuroendocrine carcinoma	29 (10.1%)
Small cell neuroendocrine carcinoma	109 (38.0%)
SEER Combined Mets at DX-liver, n (%)	53 (18.5%)

Grade: Grade I: well differentiated; differentiated; NOS Grade II: Moderately differentiated; moderately differentiated; intermediate differentiation; Grade IIL: Poorly differentiated; Differentiated Grade IV: Undifferentiated: Anaplastic Surveillance Epidemiology and End Results Combined Mets at DX-liver: The tumor metastasized to the liver. GB-NEC: Gallbladder neuroendocrine carcinoma; GB-ADC: Gallbladder adenocarcinoma; SEER: Surveillance Epidemiology and End Results.